Tislelizumab in People With Colorectal Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The researchers are doing this study to find out whether tislelizumab is an effective treatment for people with colorectal cancer who are living in Nigeria. The researchers will also look at the safety of the study drug. All participants in this study will be treatment naïve (they have not yet received treatment for their cancer), and their cancer will be mismatch repair deficient (dMMR). dMMR cancer can happen when your cells are unable to repair mistakes made during the cell division process.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Stan zdrowia pozwalający na uczestnictwo w badaniu (ECOG 0-1)
- •Dla kobiet: negatywny wynik testu ciąży wykonany w ciągu 72 godzin przed rozpoczęciem leczenia
- •Dla kobiet: chęć stosowania niezawodnej antykoncepcji przez czas badania i co najmniej 120 dni po ostatniej dawce leku
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
Memorial Sloan Kettering Cancer Center
New York, United States
Lagos University Teaching Hospital
Idi-Araba, Nigeria
Obafemi Awolowo University Teaching Hospital
Ile-Ife, Nigeria
Trial contact
Fiyinfolu O Balogun, MD, PhD
Peter Kingham, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.